CHRISTIE FLAMINI: Open Payments
NPI 1447934195 · ROYAL OAK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 35 payments from 16 companies in 2025. Trend: 2023 $290 · 2024 $593 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $157 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| ABBVIE INC. | 4 | $74 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Alkermes, Inc. | 2 | $51 |
| Bausch Health US, LLC | 2 | $47 |
| Corium, LLC | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, REXULTI, INGREZZA, ARISTADA, APLENZIN, Azstarys, UZEDY.
Industry payments across MI — which companies pay providers there.
